Interv Akut Kardiol. 2020;19(3):156-160 | DOI: 10.36290/kar.2020.009

Optimal pharmacotherapy following percutaneous coronary intervention for chronic coronary artery disease

Pavel Červinka

Klinika kardiologie Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., a UJEP, Ústí nad Labem

Cardiovascular diseases are responsible for the majority of deaths in the developed countries as well as in the Czech Republic. Pharmacotherapy after PCI in patients with chronic CAD must be tailored to the individual patient with respect to patient characteristics (age, history of MI, presence of other risk factors, etc.), coronary involvement and systolic function of the left ventricle (single versus multivessel disease, completeness of revascularization, preserved or depressed left ventricular systolic function), and with respect to the percutaneous procedure itself (number of stents, bare versus drug-eluting stents, bifurcation stenosis, left main PCI, etc.). The goal of the treatment is pain relief and improvement of the patient's outcome.

Keywords: percutaneous coronary intervention, chronic coronary artery disease, dual antiplatelet treatment, oral anticoagulant treatment, non-pharmacologic modification of risk factors.

Received: April 14, 2020; Revised: April 14, 2020; Accepted: April 22, 2020; Prepublished online: April 22, 2020; Published: September 2, 2020  Show citation